Bayer takes Alport syndrome drug into phase 2

Bayer takes Alport syndrome drug into phase 2

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome, a rare, genetic disease that leads to chronic kidney disease (CKD). Alport is caused by mutations in genes that are involved in the formation of type IV collagen, a protein integral to…

Read More